Welcome to the ICON6 website

This website is designed to provide information about the ICON6 trial.

Overview

ICON6 is a randomised three-arm, three stage, double-blind, placebo-controlled multi-centre Gynaecologic Cancer InterGroup (GCIG) phase III trial.  

ICON6 is designed to evaluate the safety and efficacy of platinum-based chemotherapy in combination with cediranib in women with platinum-sensitive relapsed ovarian cancer . Cediranib is an oral targeted small molecule inhibitor of a key signalling molecule Vascular Endothelial Growth Factor (VEGF) which is an oral inhibitor of tyrosine kinase (TK) activity and acts through blockade of the TK receptor. Cediranib (AZD2171) will be administered during platinum-based chemotherapy only (concurrent cediranib), or given during chemotherapy and continued as single agent maintenance therapy (concurrent and maintenance cediranib). 

Link to Page IconRead more about us

Latest News

ICON6 Final Progression Free Survival analysis presented at The European Cancer Congress (ECCO 17 - ESMO 38 - ESTRO 32) 2013

The ICON6 Chief Investigator Professor Jonathan Ledermann presented the results of the final Progression Free Survival analysis at The European Cancer Congress in Amsterdam on 30th September 2013.  The full abstract is available at the link below, just enter "ICON6" into the field labelled 'Abstract Title' and then click the 'Search' button to find the abstract.

ICON6 Abstract for The European Cancer Congress 2013

ICON6 selected for The European Cancer Congress media programme

ICON6 was selected for inclusion in The European Cancer Congress media programme. The full press release is available at the link below:

ICON6 Press Release for The European Cancer Congress 2013

A video of the ICON6 Chief Investigator Professor Jonathan Ledermann presenting the Progression Free Survival results of the ICON6 trial to the media is also available at the link below:

Video of ICON6 Presentation to the media at The European Cancer Congress 2013

Link to Page IconRead more

Latest Updates

Accrual

The ICON6 trial closed to recruitment in December 2011.  

Total number of patients recruited:

486

[Read more about Accrual]